Biosyent (RX) investor relations material

Executive summary

• Q1 2026 revenue rose 27% year-over-year to CAD 13.9 million, driven by the Oral Science acquisition and growth in pharmaceutical sales.

• EBITDA for Q1 2026 was just over CAD 3.6 million, up 14% year-over-year; adjusted EBITDA grew 22% after excluding one-time costs.

• Net income after tax for Q1 2026 was CAD 2.345 million, up 1% year-over-year; adjusted NIAT up 20% year-over-year.

• Fully diluted EPS for Q1 2026 was CAD 0.20; adjusted EPS was CAD 0.24; trailing 12 months EPS was CAD 0.78.

• Oral Science contributed one month of revenue and profit in Q1 2026, with CAD 3 million in sales and CAD 500,000 EBITDA.

Financial highlights

• Oral Science's 2025 audited results: CAD 31 million revenue, CAD 4.4 million EBITDA.

• Pro forma 12-month revenue would have exceeded CAD 70 million, with CAD 16.5 million EBITDA.

• Q1 2026 pharmaceutical sales increased 1% year-over-year, with Canadian pharma up 9% and international pharma down 44% due to prior year backlog.

• Insecticide segment sales declined 58% year-over-year for Q1 but grew 59% on a TTM basis.

• Return on equity for TTM ended March 31, 2026 was 22%.

Outlook and guidance

• Expect cash position to recover to pre-acquisition levels by end of next year due to strong cash generation.

• Debt from Oral Science acquisition expected to be fully repaid by September 2026.

• Initiatives underway to expand oral health business internationally and ongoing innovation in FeraMAX product line.

• Management remains focused on profitable growth and long-term value creation amid ongoing geopolitical and trade uncertainties.